{"nctId":"NCT01730534","briefTitle":"Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events","startDateStruct":{"date":"2013-04-25","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Non-Insulin-Dependent","High Risk for Cardiovascular Event"],"count":17190,"armGroups":[{"label":"Dapagliflozin","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin 10 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo tablet"]}],"interventions":[{"name":"Dapagliflozin 10 mg","otherNames":[]},{"name":"Placebo tablet","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures\n* Female or male aged ≥40 years\n* Diagnosed with Type 2 Diabetes\n* High Risk for Cardiovascular events\n\nExclusion Criteria:\n\n* Diagnosis of Type 1 diabetes mellitus History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time\n* Chronic cystitis and/or recurrent urinary tract infections\n* Pregnant or breast-feeding patients","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke","description":"Safety and co-primary efficacy","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"756","spread":null},{"groupId":"OG001","value":"803","spread":null}]}]}]},{"type":"PRIMARY","title":"Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.","description":"Co-primary efficacy","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"417","spread":null},{"groupId":"OG001","value":"496","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Included in the Renal Composite Endpoint: Confirmed Sustained ≥40% Decrease in eGFR to eGFR <60 ml/Min/1.73m2 and/or ESRD and/or Renal or CV Death.","description":"Secondary","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"370","spread":null},{"groupId":"OG001","value":"480","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Included in the Endpoint of All-cause Mortality.","description":"Secondary","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"529","spread":null},{"groupId":"OG001","value":"570","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3205,"n":8574},"commonTop":["Renal impairment","Acute kidney injury","Chronic kidney disease"]}}}